NCT05188313View on ClinicalTrials.gov

TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer

PHASE3RecruitingINTERVENTIONAL
Enrollment

376

Participants

Timeline

Start Date

March 9, 2022

Primary Completion Date

July 31, 2027

Study Completion Date

February 28, 2037

Conditions
Esophageal CancerEsophageal Adenocarcinoma
Interventions
DRUG

Trastuzumab

Intravenous administration of study drug

DRUG

Pertuzumab

Intravenous administration of study drug

DRUG

Paclitaxel

Intravenous administration of study drug

DRUG

Carboplatin

Intravenous administration of study drug

Trial Locations (1)

1105 AZ

RECRUITING

Academic Medical Center, Amsterdam

All Listed Sponsors
lead

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

OTHER